一、会议召开情况 可孚医疗科技股份有限公司（以下简称"公司"）第二届监事会第十五次会 议于 2025 年 8 月 3 日以电话方式发出会议通知，会议于 2025 年 8 月 7 日上午 11:00 在公司六楼会议室以现场会议方式召开。会议应出席监事 3 人，实际出席 监事 3 人，公司董事会秘书列席了会议。本次会议由监事会主席曾子云先生主 持。会议的召集和召开符合《中华人民共和国公司法》等法律法规和《公司章程》 的有关规定。 证券代码：301087 证券简称：可孚医疗 公告编号：2025-046 可孚医疗科技股份有限公司 第二届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二、监事会会议审议情况 与会监事对本次会议需审议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于公司发行 H 股股票并在香港联合交易所有限公司主板 上市的议案》 为加快推进公司全球化战略布局，提升公司海外业务拓展能力，进一步提升 公司品牌形象及知名度，根据相关法律法规、规范性文件的要求，公司拟发行境 外上市外资股（H 股）并申请在香港联合交易所有 ...

来源：金融界 主力资金净流出居前的分别为安必平（1174.99万元）、东富龙（1070.65万元）、安杰思（995.13万 元）、微电生理（983.9万元）、可孚医疗（916.41万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.71-0.031.07亿元7.18%2300003 乐普医疗17.276.931.07亿元5.73%3301363美好医疗20.037.175599.57万元11.04%4603987康德莱 9.235.734851.48万元12.43%5870199倍益康42.581.383949.32万元7.52%6002551尚荣医疗4.649.953736.73 万元22.93%7688068热景生物243.022.543614.97万元6.9%8688314康拓医疗40.08.113278.73万元 15.1%9688108赛诺医疗20.4420.022762.62万元19.98%10832278鹿得医疗12.484.962727.93万元13.05% 8月8日，医疗器械行业上涨0.93%，今日主力资金流出6.11亿元，成分股59只上涨，39只下跌。 ...

Group 1 - The core viewpoint of the article highlights that Kefu Medical's stock price has decreased by 0.97% to 37.59 yuan as of August 6, 2025, with a trading volume of 24,400 hands and a turnover of 92 million yuan [1] - Kefu Medical specializes in the research, production, and sales of medical devices, covering areas such as rehabilitation care, medical electronics, and consumables [1] - The company is planning to list in Hong Kong, with a current market value of approximately 7.9 billion yuan [1] Group 2 - Market rumors suggest that regulatory authorities may raise the market capitalization threshold for A-share companies to list in Hong Kong to 20 billion yuan, which could impact smaller companies [1] - On August 6, a block trade occurred involving 230,500 shares, amounting to 8.31 million yuan, at a discount of 4.07% [1] - On the same day, the net outflow of main funds was 16.38 million yuan, accounting for 0.22% of the circulating market value, while the net inflow over the past five days was 11.95 million yuan, representing 0.16% of the circulating market value [1]

Group 1 - The core viewpoint of the article highlights the increasing trend of A-share companies, led by industry giants like CATL, pursuing IPOs in Hong Kong, while smaller companies face pressure due to low market capitalization [1][2] - Regulatory authorities are considering setting a minimum market capitalization requirement for A-share companies seeking to list in Hong Kong, potentially raising the threshold from 10 billion RMB to 20 billion RMB [1][5] - As of now, over 40 A-share companies have officially submitted applications to the Hong Kong Stock Exchange, with 30 more announcing related processes, indicating a significant interest in the A+H listing model [1][2] Group 2 - A notable trend is the surge of small-cap stocks announcing plans for A+H listings, with at least 30 A-share companies revealing their intentions, many of which have market capitalizations between 5 billion RMB and 8 billion RMB [2][3] - The majority of these small-cap companies are from sectors such as technology, pharmaceuticals, and artificial intelligence, reflecting a shift towards internationalization and access to global capital [3][6] - Analysts suggest that the potential increase in market capitalization requirements could lead to a more selective process for companies pursuing Hong Kong listings, ensuring that only stronger firms participate [4][7] Group 3 - The article discusses the mixed stock price performance of small-cap companies following their announcements to pursue Hong Kong listings, with some experiencing slight increases while others saw declines [3] - Experts argue that setting a market capitalization threshold is reasonable as it would filter for higher-quality companies, enhancing the attractiveness of the Hong Kong market to global investors [5][6] - The emphasis on industry leaders for Hong Kong listings aligns with the regulatory focus on supporting robust companies, which may lead to a more sustainable IPO environment [6][7]

可孚医疗最新一期业绩显示，截至2025一季报，公司营业总收入7.38亿元、同比减少8.59%，归属净利 润9142.51万元，同比减少9.68%，扣非净利润6852.25万元，同比减少25.34%，流动比率2.887、速动比 率2.419、资产负债率23.52%。 天眼查商业履历信息显示，可孚医疗科技股份有限公司，成立于2009年，位于长沙市，是一家以从事专 用设备制造业为主的企业。企业注册资本20909.2万人民币，实缴资本20909.2万人民币。公司法定代表 人为张敏。 金融界消息 截至2025年8月5日收盘，可孚医疗（301087）报收于37.96元，下跌1.43%，换手率1.64%， 成交量3.18万手，成交金额1.21亿元。 资金流向方面，今日主力资金净流出1343.95万元，占比成交额11.08%。其中，超大单净流出480.90万 元、占成交额3.97%，大单净流出863.05万元、占成交额7.12%，中单净流出流入598.14万元、占成交额 4.93%，小单净流入745.80万元、占成交额6.15%。 通过天眼查大数据分析，可孚医疗科技股份有限公司共对外投资了30家企业，参与招投标项目267次， ...

Core Viewpoint - The stock price of Kefu Medical closed at 37.96 yuan on August 5, 2025, reflecting a decline of 1.43% from the previous trading day [1] Company Overview - Kefu Medical specializes in the research, development, production, and sales of medical devices, with products spanning rehabilitation care, medical electronics, and consumables [1] - The company operates within the medical device sector and is part of the Hunan region market [1] Market Activity - On August 5, the trading volume for Kefu Medical was 31,767 hands, with a transaction amount of 1.21 billion yuan, resulting in a turnover rate of 1.64% [1] - Recent data indicates a net outflow of main funds amounting to 13.44 million yuan on August 5, which represents 0.18% of the circulating market value [1] - However, over the past five days, the overall trend for main funds has shown a net inflow of 33.91 million yuan, accounting for 0.46% of the circulating market value [1]

Group 1 - The stock price of Kefu Medical reached 38.51 yuan as of August 4, 2025, with an increase of 0.12 yuan, representing a rise of 0.31% [1] - The trading volume on that day was 37,018 hands, with a transaction amount of 141 million yuan and a fluctuation of 4.56% [1] - Kefu Medical operates in the medical device industry, focusing on the research, production, and sales of medical equipment and consumables [1] Group 2 - As of July 31, 2025, Kefu Medical had approximately 19,000 shareholders [1] - The company is one of the 17 A-share listed companies that announced plans for an IPO in Hong Kong in July [1] - On August 4, the net inflow of main funds into Kefu Medical was 6.59 million yuan, accounting for 0.09% of the circulating market value [1] Group 3 - Over the past five trading days, the cumulative net inflow of main funds was 49.34 million yuan, representing 0.66% of the circulating market value [1]

证券日报网讯可孚医疗（301087）8月4日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东总户数约1.9万户。 ...

Company Overview - Cofoe Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, with key products including blood glucose systems, uric acid systems, blood pressure monitors, and various other medical instruments and supplies [2]. Financial Performance - For Q1 2025, the company reported revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.43 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]. Market Position - As of August 1, Cofoe Medical's stock closed at 38.39 yuan, up 4.09%, with a rolling price-to-earnings (PE) ratio of 26.58, marking a new low in 107 days. The company's total market capitalization is 8.027 billion yuan [1]. - In comparison to the medical device industry, which has an average PE of 53.65 and a median of 37.22, Cofoe Medical ranks 53rd in terms of PE [1][3]. Shareholder Information - As of June 20, 2025, Cofoe Medical has 19,000 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].

金融界消息 截至2025年8月1日收盘，可孚医疗（301087）报收于38.39元，上涨4.09%，换手率2.68%， 成交量5.21万手，成交金额1.99亿元。 资金流向方面，今日主力资金净流入3720.16万元，占比成交额18.72%。其中，超大单净流入1151.70万 元、占成交额5.79%，大单净流入2568.46万元、占成交额12.92%，中单净流出流出1516.55万元、占成 交额7.63%，小单净流出2203.61万元、占成交额11.09%。 天眼查商业履历信息显示，可孚医疗科技股份有限公司，成立于2009年，位于长沙市，是一家以从事专 用设备制造业为主的企业。企业注册资本20909.2万人民币，实缴资本20909.2万人民币。公司法定代表 人为张敏。 通过天眼查大数据分析，可孚医疗科技股份有限公司共对外投资了30家企业，参与招投标项目265次， 知识产权方面有商标信息616条，专利信息431条，此外企业还拥有行政许可2305个。 来源：金融界 可孚医疗最新一期业绩显示，截至2025一季报，公司营业总收入7.38亿元、同比减少8.59%，归属净利 润9142.51万元，同比减少9.68%，扣非净 ...